Andrew Paul Mazar

US Patent:

20090170123, Jul 2, 2009

Filed:

Oct 23, 2006

Appl. No.:

12/091003

Inventors:

Fernando Donate - San Diego CA, US
Jose C. Juarez - San Diego CA, US
Andrew P. Mazar - Highland Park IL, US

International Classification:

G01N 33/53
C12Q 1/02

US Classification:

435 72, 435 29

Abstract:

The present invention in the field of biochemistry and medicine is directed to novel methods for identifying molecules, typically proteins, that move to the cell surface when cells are stimulated or stressed can act as receptors even thought they are not transmembrane molecules and normally originate in the cytosol. Such molecules are useful targets for development of agents that can image or treat tumors or other pathologies. Methods to detect or identify such proteins that have translocated to the cell surface when cells are stressed by an angiogenic environment, environmental stresses, the stimulation of cell proliferation and differentiation, or after exposure to certain drugs such as cancer chemotherapeutics, are disclosed.

US Patent:

20090264628, Oct 22, 2009

Filed:

Oct 3, 2006

Appl. No.:

12/089166

Inventors:

Mingdong Huang - Newton MA, US
Qing Huai - Medford MA, US
Graham C. Parry - San Mateo CA, US
Douglas B. Cines - Wynnewood PA, US
Andrew P. Mazar - Highland Park IL, US

Assignee:

Beth-Israel Deaconess Medical Center , Inc. - Boston MA
Attenuon LLC - San Diego CA
The University of Pennsylvania - Philadelphia PA

International Classification:

C07K 16/00
G06G 7/48

US Classification:

5303911, 703 11

Abstract:

Urokinase-type plasminogen activator (uPA) binds its cellular receptor (uPAR) with high affinity, thus localizing the generation of plasmin from plasminogen on the surface of a variety of cells. Disclosed herein is the structure of suPAR (uPAR) complexed with the amino terminal fragment (ATF) of uPA (uPA) at a resolution of 1.9 ú by X-ray crystallography. Three consecutive domains of uPAR (D1, D2 and D3) form the shape of a thick-walled teacup with a cone shape cavity in the middle, which has a wide opening (25 ú) and large depth (14 ú). uPAinserts into the cavity of uPAR and forms a large interface. The structure provides the basis for high affinity binding between uPA and uPAR and suggests the D1 and D2 domain of uPAR and the GFD domain of uPA (uPA) are primarily responsible for uPA-uPAR binding. This structure presents the first high resolution view of uPA-uPAR interaction, and provides, among other things, a new platform for designing uPA-uPAR inhibitors/antagonists.

US Patent:

20110020434, Jan 27, 2011

Filed:

Sep 8, 2010

Appl. No.:

12/877414

Inventors:

Thomas V. O'Halloran - Chicago IL, US
Haimei Chen - Chicago IL, US
Andrew Mazar - Highland Park IL, US

International Classification:

A61K 9/127
A61K 33/36
A61K 31/285
A61K 31/282
A61K 33/24
A61K 38/19
A61K 39/395
A61P 35/00

US Classification:

424450, 424623, 514504, 514492, 424649, 424 851, 4241301

Abstract:

The present invention relates to nanoparticle encapsulated arsenic and platinum compositions and methods of use thereof. In particular, the present invention provides co-encapsulation of active forms of arsenic and platinum drugs into liposomes, and methods of using such compositions for the diagnosis and treatment of cancer.

US Patent:

20230062278, Mar 2, 2023

Filed:

Dec 23, 2020

Appl. No.:

17/789321

Inventors:

- Fort Worth TX, US
Andrew MAZAR - Lake Forest IL, US

International Classification:

A61K 31/407
A61K 31/519

Abstract:

The present invention provides methods of treating myelofibrosis in a patient by administering to the patient a therapeutically effective amount of a 08K-3β inhibitor such as 3-(5-fluorobenzofuran-3-y1)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-y1)pynOle-2,5-dione, or a pharmaceutically acceptable salt thereof, optionally in combination with a therapeutically effective amount of a JAK inhibitor such as ruxolitinib, or a pharmaceutically acceptable salt thereof.

US Patent:

20210251897, Aug 19, 2021

Filed:

Oct 3, 2019

Appl. No.:

16/592263

Inventors:

- Evanston IL, US
Haimei Chen - Evanston IL, US
Andrew Mazar - Highland Park IL, US

International Classification:

A61K 9/127
A61K 47/69
A61K 38/40
A61K 33/36
A61K 45/06
A61K 33/24
C07K 16/28
A61K 38/19
C07F 15/00
A61K 31/282
C07F 9/72

Abstract:

The present invention relates to nanoparticle encapsulated arsenic and platinum compositions and methods of use thereof. In particular, the present invention provides co-encapsulation of active forms of arsenic and platinum drugs into liposomes, and methods of using such compositions for the diagnosis and treatment of cancer.

US Patent:

20140220115, Aug 7, 2014

Filed:

Apr 7, 2014

Appl. No.:

14/246678

Inventors:

- Evanston IL, US
Haimei Chen - Evanston IL, US
Andrew Mazar - Highland Park IL, US

Assignee:

NORTHWESTERN UNIVERSITY - Evanston IL

International Classification:

A61K 9/127
C07F 15/00
C07F 9/72
A61K 31/282

US Classification:

424450, 514492, 556136, 556 30, 514504

Abstract:

The present invention relates to nanoparticle encapsulated arsenic and platinum compositions and methods of use thereof. In particular, the present invention provides co-encapsulation of active forms of arsenic and platinum drugs into liposomes, and methods of using such compositions for the diagnosis and treatment of cancer.